Avalyn Pharma: Funding, Investors & Team (Oct 2026)
Avalyn Pharma, headquartered in Seattle, Washington, is a biopharma company dedicated to progressing treatments for Idiopathic Pulmonary Fibrosis (IPF) and various other serious respiratory disorders. The company focuses on swiftly advancing AP01 as a therapy for IPF, offering further potential treatments for IPF through its pipeline, enhancing the management and results of severe respiratory diseases, and creating innovative inhaled therapeutics. Founded in 2011, Avalyn Pharma is committed to advancing respiratory health.
Avalyn Pharma has raised $275M across 2 funding rounds on record, the most recent a Series D of $100M announced in Jul 2025.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Avalyn Pharma Company Profile and Key Stats
Latest funding round on record: Jul 2025.
Avalyn Pharma Funding Rounds
Avalyn Pharma raised $175M in a Series C announced in Sep 2023.
1.8 years later, a Series D of $100M was announced in Jul 2025.
Avalyn Pharma Founders and Leadership Team
Contact details for the Avalyn Pharma team: 1 of 1 has an email address on file.
Start 14-day free trial →Avalyn Pharma Funding Compared to Other Biotechnology Startups
Avalyn Pharma's latest round of $100M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Avalyn Pharma in Biotechnology and Seattle
Companies Similar to Avalyn Pharma
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Avalyn Pharma Funding FAQs
What does Avalyn Pharma do?
Avalyn Pharma, headquartered in Seattle, Washington, is a biopharma company dedicated to progressing treatments for Idiopathic Pulmonary Fibrosis (IPF) and various other serious respiratory disorders. The company focuses on swiftly advancing AP01 as a therapy for IPF, offering further potential treatments for IPF through its pipeline, enhancing the management and results of severe respiratory diseases, and creating innovative inhaled therapeutics. Founded in 2011, Avalyn Pharma is committed to advancing respiratory health.
How much funding has Avalyn Pharma raised?
Avalyn Pharma has raised $275M across 2 rounds on record. The most recent is a Series D of $100M announced in Jul 2025.
When did Avalyn Pharma last raise funding?
Avalyn Pharma's most recent funding round on record is a Series D of $100M, announced in Jul 2025.
Who founded Avalyn Pharma?
FundedIQ lists Mark W Surber (Founder) at Avalyn Pharma.
Where is Avalyn Pharma headquartered?
Avalyn Pharma is based in Seattle, Washington, United States.
How many employees does Avalyn Pharma have?
Avalyn Pharma is in the 11-50 employee band.
How does Avalyn Pharma's funding compare to other Biotechnology startups?
Avalyn Pharma's latest round of $100M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Avalyn Pharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Avalyn Pharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.